Intellia Therapeutics NTLA

Name: NTLA Crucible Score
Creator: Kaladin Capital Intelligence

UnknownUnknownN/A📅 Scored March 14, 2026

Price at analysis: $13.72

Crucible Score

46.4

C-

Quality × Value Composite

KQI — Quality

47.1

C-

Fundamental Quality Index

KVI — Value

45.5

D+

Valuation Attractiveness Index

Crucible Verdict — NTLA

Intellia Therapeutics earns a mediocre C- rating despite strong growth prospects, as poor financial quality and weak market position offset its promising gene-editing pipeline. NTLA trades at a 35% discount to fair value with Nobel laureate Jennifer Doudna at the helm for two years. The key catalyst will be whether management can convert its 70-rated growth profile into sustainable commercial success.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality⚠

18.8

Growth Profile⚠

70.0

Moat Durability

62.1

Management Effectiveness

53.4

Diversification & Resilience

28.8

Market Position

28.0

Weakest dimension: Financial Quality (18.8)

◆ KVI Value Dimensions

DCF Margin of Safety

68.3

FCF Yield & Cash Returns

30.8

Relative Valuation

36.5

Growth-Adjusted Value

35.0

Historical Valuation

50.0

Macro Context

14.0

◆ DCF Valuation Scenarios

Bear Case

$4.12

Base Case

$18.53

Bull Case

$48.70

Price at Analysis

$13.72

Scenario	Fair Value	Rev CAGR (5yr)	Terminal Margin	WACC
🔴 Bear	$4.12	25.0%	20.0%	16.5%
🟢 Base	$18.53	45.0%	30.0%	15.5%
🟢 Bull	$48.70	65.0%	40.0%	14.5%

Key Assumptions: NTLA is a pre-commercial CRISPR gene-editing biotech with deep cash burn (~$350-400M/yr FCF) and minimal collaboration revenue (~$33-68M). The DCF hinges on successful commercialization of NTLA-2002 (hereditary angioedema) and pipeline assets driving revenue inflection from ~$68M to $500M-$2.5B+ over 10 years depending on scenario. WACC is elevated (14.5-16.5%) reflecting high beta of 2.02 and significant clinical/regulatory risk; bear case assumes limited pipeline success with one modest product, base assumes one blockbuster plus pipeline contributions, and bull assumes multiple blockbuster approvals with strong market penetration.

◆ Financial Snapshot

Profitability

Gross Margin-25.6%

Operating Margin-651.7%

Net Margin-609.9%

ROIC-55.9%

ROE-36.2%

Balance Sheet

Balance SheetCR: 5.08

Cash Conversion

Capital IntensityCapex/Rev: 8.5%

Altman Z-Score-0.00 (Distress)

Piotroski F-Score2/9 (Weak)

Growth

Revenue CAGR19.6% CAGR

Earnings CAGRInsufficient data

Growth ConsistencyCV: 1.52

Segment BreadthNo data

Quarterly TrendRev∆, Margin↑, Exp↓

Earnings CredibilityConsistent Beater

◆ Analyst Consensus & Leadership

Leadership & Governance

CEOJennifer Doudna · 2 years

CEO Ownership3.1%

Compensation94% performance-based

Insider ActivityBuying

Earnings Beat Rate79% (17/22)

◆ Related Companies in Our Universe

Other Unknown companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+

Methodology All Scores Crucible Briefs Performance @KaladinCI

Analysis conducted March 14, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.